2017
Pharmacogenomics of off‐target adverse drug reactions
Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA, Phillips EJ. Pharmacogenomics of off‐target adverse drug reactions. British Journal Of Clinical Pharmacology 2017, 83: 1896-1911. PMID: 28345177, PMCID: PMC5555876, DOI: 10.1111/bcp.13294.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsSevere cutaneous adverse reactionsTarget adverse drug reactionsDrug reactionsImmunological memoryTherapeutic effectHuman leukocyte antigen (HLA) associationsCutaneous adverse reactionsStrong human leukocyte antigen (HLA) associationDrug therapeutic effectsIM-ADRsMaculopapular exanthemaClinical featuresOptimal therapySignificant morbidityAdverse reactionsAntigen associationsPharmacological actionsTherapeutic targetDisease pathophysiologyClinical phenotypePreclinical testingGreater riskDrug metabolismPatient safety
1996
Increased sensitivity to bradykinin among African Americans
Gainer J, Nadeau J, Ryder D, Brown N. Increased sensitivity to bradykinin among African Americans. Journal Of Allergy And Clinical Immunology 1996, 98: 283-287. PMID: 8757204, DOI: 10.1016/s0091-6749(96)70151-3.Peer-Reviewed Original ResearchConceptsKallikrein-kinin systemWheal responseAfrican AmericansLife-threatening side effectsTissue kallikrein-kinin systemACE inhibitor-associated angioedemaACE inhibitor doseMechanisms of angioedemaDouble-blind fashionDoses of bradykininAfrican American raceNormotensive African AmericansUrinary kallikrein levelsACE inhibitor-induced increaseInhibitor-induced increaseBradykinin doseConcurrent medicationsEssential hypertensionKallikrein levelsBradykinin levelsExogenous bradykininIntradermal injectionAmerican raceSide effectsInhibitor dose